<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02348606</url>
  </required_header>
  <id_info>
    <org_study_id>14-003</org_study_id>
    <nct_id>NCT02348606</nct_id>
  </id_info>
  <brief_title>&quot;Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA&quot;</brief_title>
  <acronym>OSA</acronym>
  <official_title>A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jazz Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a 12 week, randomized, double-blind, placebo controlled, multicenter, 5-arm
      parallel group study of safety and efficacy of JZP-110 in the treatment of excessive
      sleepiness in adult subjects with OSA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to Week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ESS Score From Baseline to Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 12. A negative change from baseline represents improvement in excessive sleepiness.
The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 12. PGIc was rated by subjects and measures the change in their condition since start of treatment on a 7-point scale ranging from 1 = very much improved to 7 = very much worse.
This is the key secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep Latency Time on Each of the 5 MWT Trials at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-minute MWT From Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ESS Score From Baseline to Week 1, Week 4, and Week 8</measure>
    <time_frame>Baseline to Weeks 1, 4, and 8</time_frame>
    <description>Change in Epworth Sleepiness Scale (ESS) score from Baseline to Weeks 1, 4, and 8. A negative change from baseline represents improvement in excessive sleepiness.
The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Reported as Improved on the PGIc at Week 1, Week 4, and Week 8</measure>
    <time_frame>Weeks 1, 4, and 8</time_frame>
    <description>Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 1, Week 4, and Week 8. PGIc was rated by subjects and measures the change in their condition since treatment start on a 7-point scale ranging from 1 = very much improved to 7 = very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Reported as Improved on the Clinical Global Impression of Change (CGIc) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of subjects reported as improved (minimally, much, or very much) on the CGIc at Week 12. CGIc was rated by clinicians and measures the change in the subject's condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Reported as Improved on the CGIc at Week 1, Week 4, and Week 8</measure>
    <time_frame>Weeks 1, 4, and 8</time_frame>
    <description>Percentage of subjects reported as improved (minimally, much, or very much) on the CGIc at Week 1, Week 4, and Week 8. CGIc was rated by clinicians and measures the change in the subject's condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">476</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>37.5 mg of JZP-110</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once Daily Dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 mg of JZP-110</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once Daily Dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg of JZP-110</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once Daily Dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg of JZP-110</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once Daily Dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once Daily Dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JZP-110</intervention_name>
    <arm_group_label>150 mg of JZP-110</arm_group_label>
    <arm_group_label>300 mg of JZP-110</arm_group_label>
    <arm_group_label>37.5 mg of JZP-110</arm_group_label>
    <arm_group_label>75 mg of JZP-110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          1. Male or female between 18 and 75 years of age, inclusive

          2. Diagnosis of OSA according to ICSD-3 criteria

          3. Body mass index from 18 to &lt;45 kg/m2

          4. Consent to use a medically acceptable method of contraception

          5. Willing and able to provide written informed consent

        Major Exclusion Criteria:

          1. Female subjects who are pregnant, nursing, or lactating

          2. Any other clinically relevant medical, behavioral, or psychiatric disorder other than
             OSA that is associated with excessive sleepiness

          3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia,
             schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5
             criteria

          4. History or presence of any acutely unstable medical condition, behavioral or
             psychiatric disorder (including active suicidal ideation), or surgical history that
             could affect the safety of the subject or interfere with study efficacy, safety, PK
             assessments, or the ability of the subject to complete the trial per the judgment of
             the Investigator.

          5. History of bariatric surgery within the past year or a history of any gastric bypass
             procedure

          6. Presence or history of significant cardiovascular disease

          7. Use of any over-the-counter (OTC) or prescription medications that could affect the
             evaluation of excessive sleepiness

          8. Received an investigational drug in the past 30 days or five half-lives

          9. Previous exposure to or participation in a clinical trial of JZP-110 (ADX-N05,
             R228060, or YKP10A)

         10. History of phenylketonuria (PKU) or history of hypersensitivity to
             phenylalanine-derived products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pulmonary Associates</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Research Partners</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>So Cal Institute For Respiratory Diseases, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Sleep Medicine</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Center for Narcolepsy</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAB Clinical Research</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Group of St. Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Pediatric Research Institute</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SleepMed of Central Georgia</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago College of Nursing</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Research Group</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Sleep &amp; Wake Disorders</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurocare, Inc.</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>24590</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital Sleep Disorders &amp; Research Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neurophysiology Services</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Medicine &amp; Research Center, St. Luke's Hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clayton Sleep Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinilabs</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hickory Research Center</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hickory Research Center, ARSM Research, LLC</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northcoast Clinical Trials Inc.</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Management Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Cleveland Sleep Research Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Sleep Medicine &amp; Neuroscience Institute</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy St. Anne &amp; Mercy St. Charles Sleep Disorders Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Med of South Carolina</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Neurology LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Todd J. Swick</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Therapy &amp; Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagra Clinical Research</name>
      <address>
        <city>Niagra Falls</city>
        <state>Ontario</state>
        <zip>L2E 7H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sleep Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4P 1P2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Psychiatric Research Foundation</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5K 2A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Sleep Research Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J 3S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universite Paris 5 Hôtel-Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat - Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>medbo Bezirksklinikum Regensburg Schlafmedizinisches Zentrum</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster Department für Neurologie</name>
      <address>
        <city>Muenster</city>
        <state>North Rhine-Westphalia</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Sleep Research GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Wilhelmshoehe</name>
      <address>
        <city>Kassel</city>
        <zip>34131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somni bene GmbH Institut für Medizinische Forschung und Schlafmedizin Schwerin GmbH</name>
      <address>
        <city>Schwerin</city>
        <zip>19053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Wake Center SEIN Heemstede</name>
      <address>
        <city>Heemsteded</city>
        <state>Noord Holland</state>
        <zip>2103 SW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <results_first_submitted>April 19, 2019</results_first_submitted>
  <results_first_submitted_qc>July 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2019</results_first_posted>
  <disposition_first_submitted>November 16, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>November 16, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 20, 2017</disposition_first_posted>
  <last_update_submitted>July 21, 2019</last_update_submitted>
  <last_update_submitted_qc>July 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02348606/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02348606/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Note: 476 subjects were enrolled and randomized, however 2 subjects never received drug. This resulted in 474 subjects comprising the safety population.</recruitment_details>
      <pre_assignment_details>During screening, subjects completed a medical exam. An overnight Polysomnography (PSG) assessment followed by MWT and 24-hour ABPM were conducted at baseline. After successful completion of the screening and baseline visits subjects were randomized in a 1:1:2:2:2 ratio to receive 37.5, 75, 150, or 300 mg JZP- 110 or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>37.5 mg of JZP-110</title>
          <description>37.5 mg JZP-110 administered orally, once daily (QD), for the 12-week treatment phase.</description>
        </group>
        <group group_id="P2">
          <title>75 mg of JZP-110</title>
          <description>75 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
        </group>
        <group group_id="P3">
          <title>150 mg of JZP-110</title>
          <description>Subjects randomized to receive 150 mg JZP-110 initially received 75 mg JZP-110 from Day 1 through Day 3 of the treatment phase, and received 150 mg JZP-110 starting on Day 4, administered orally, QD.</description>
        </group>
        <group group_id="P4">
          <title>300 mg of JZP-110</title>
          <description>Subjects randomized to receive 300 mg JZP-110 initially received 150 mg JZP-110 from Day 1 through Day 3 of the treatment phase and received 300 mg JZP-110 starting on Day 4, administered orally, QD.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo administered orally, QD, for the 12 week treatment phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="118"/>
                <participants group_id="P5" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="106"/>
                <participants group_id="P4" count="94"/>
                <participants group_id="P5" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>37.5 mg of JZP-110</title>
          <description>37.5 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
        </group>
        <group group_id="B2">
          <title>75 mg of JZP-110</title>
          <description>75 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
        </group>
        <group group_id="B3">
          <title>150 mg of JZP-110</title>
          <description>Subjects randomized to receive 150 mg JZP-110 initially received 75 mg JZP-110 from Day 1 through Day 3 of the treatment phase, and received 150 mg JZP-110 starting on Day 4, administered orally, QD.</description>
        </group>
        <group group_id="B4">
          <title>300 mg of JZP-110</title>
          <description>Subjects randomized to receive 300 mg JZP-110 initially received 150 mg JZP-110 from Day 1 through Day 3 of the treatment phase and received 300 mg JZP-110 starting on Day 4, administered orally, QD.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo administered orally, QD, for the 12 week treatment phase.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="117"/>
            <count group_id="B4" value="118"/>
            <count group_id="B5" value="119"/>
            <count group_id="B6" value="474"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.1" spread="10.19"/>
                    <measurement group_id="B2" value="54.4" spread="11.46"/>
                    <measurement group_id="B3" value="52.7" spread="10.57"/>
                    <measurement group_id="B4" value="53.2" spread="10.62"/>
                    <measurement group_id="B5" value="54.1" spread="11.41"/>
                    <measurement group_id="B6" value="53.9" spread="10.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="77"/>
                    <measurement group_id="B6" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="90"/>
                    <measurement group_id="B5" value="87"/>
                    <measurement group_id="B6" value="361"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12</title>
        <description>Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to Week 12.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Fifteen subjects in the Safety Population were excluded from the Modified Intent-to Treat (mITT) Population resulting in a total of 459 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>37.5 mg of JZP-110</title>
            <description>37.5 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>75 mg of JZP-110</title>
            <description>75 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>150 mg of JZP-110</title>
            <description>Subjects randomized to receive 150 mg JZP-110 initially received 75 mg JZP-110 from Day 1 through Day 3 of the treatment phase, and received 150 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O4">
            <title>300 mg of JZP-110</title>
            <description>Subjects randomized to receive 300 mg JZP-110 initially received 150 mg JZP-110 from Day 1 through Day 3 of the treatment phase and received 300 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally, QD, for the 12 week treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12</title>
          <description>Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to Week 12.</description>
          <population>Fifteen subjects in the Safety Population were excluded from the Modified Intent-to Treat (mITT) Population resulting in a total of 459 subjects.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" spread="1.418"/>
                    <measurement group_id="O2" value="9.08" spread="1.358"/>
                    <measurement group_id="O3" value="10.96" spread="0.973"/>
                    <measurement group_id="O4" value="12.99" spread="1.038"/>
                    <measurement group_id="O5" value="0.21" spread="0.997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in ESS Score From Baseline to Week 12</title>
        <description>Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 12. A negative change from baseline represents improvement in excessive sleepiness.
The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>37.5 mg of JZP-110</title>
            <description>37.5 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>75 mg of JZP-110</title>
            <description>75 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>150 mg of JZP-110</title>
            <description>Subjects randomized to receive 150 mg JZP-110 initially received 75 mg JZP-110 from Day 1 through Day 3 of the treatment phase, and received 150 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O4">
            <title>300 mg of JZP-110</title>
            <description>Subjects randomized to receive 300 mg JZP-110 initially received 150 mg JZP-110 from Day 1 through Day 3 of the treatment phase and received 300 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally, QD, for the 12 week treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ESS Score From Baseline to Week 12</title>
          <description>Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 12. A negative change from baseline represents improvement in excessive sleepiness.
The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.</description>
          <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="0.64"/>
                    <measurement group_id="O2" value="-5.0" spread="0.62"/>
                    <measurement group_id="O3" value="-7.7" spread="0.44"/>
                    <measurement group_id="O4" value="-7.9" spread="0.46"/>
                    <measurement group_id="O5" value="-3.3" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12</title>
        <description>Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 12. PGIc was rated by subjects and measures the change in their condition since start of treatment on a 7-point scale ranging from 1 = very much improved to 7 = very much worse.
This is the key secondary endpoint.</description>
        <time_frame>12 Weeks</time_frame>
        <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>37.5 mg of JZP-110</title>
            <description>37.5 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>75 mg of JZP-110</title>
            <description>75 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>150 mg of JZP-110</title>
            <description>Subjects randomized to receive 150 mg JZP-110 initially received 75 mg JZP-110 from Day 1 through Day 3 of the treatment phase, and received 150 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O4">
            <title>300 mg of JZP-110</title>
            <description>Subjects randomized to receive 300 mg JZP-110 initially received 150 mg JZP-110 from Day 1 through Day 3 of the treatment phase and received 300 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally, QD, for the 12 week treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12</title>
          <description>Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 12. PGIc was rated by subjects and measures the change in their condition since start of treatment on a 7-point scale ranging from 1 = very much improved to 7 = very much worse.
This is the key secondary endpoint.</description>
          <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4"/>
                    <measurement group_id="O2" value="72.4"/>
                    <measurement group_id="O3" value="89.7"/>
                    <measurement group_id="O4" value="88.7"/>
                    <measurement group_id="O5" value="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sleep Latency Time on Each of the 5 MWT Trials at Week 12</title>
        <description>Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at week 12.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>37.5 mg of JZP-110</title>
            <description>37.5 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>75 mg of JZP-110</title>
            <description>75 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>150 mg of JZP-110</title>
            <description>Subjects randomized to receive 150 mg JZP-110 initially received 75 mg JZP-110 from Day 1 through Day 3 of the treatment phase, and received 150 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O4">
            <title>300 mg of JZP-110</title>
            <description>Subjects randomized to receive 300 mg JZP-110 initially received 150 mg JZP-110 from Day 1 through Day 3 of the treatment phase and received 300 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally, QD, for the 12 week treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sleep Latency Time on Each of the 5 MWT Trials at Week 12</title>
          <description>Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at week 12.</description>
          <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trial 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="1.881"/>
                    <measurement group_id="O2" value="5.77" spread="1.808"/>
                    <measurement group_id="O3" value="10.87" spread="1.284"/>
                    <measurement group_id="O4" value="12.48" spread="1.401"/>
                    <measurement group_id="O5" value="-0.40" spread="1.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" spread="1.928"/>
                    <measurement group_id="O2" value="9.47" spread="1.849"/>
                    <measurement group_id="O3" value="11.91" spread="1.332"/>
                    <measurement group_id="O4" value="14.94" spread="1.425"/>
                    <measurement group_id="O5" value="-0.44" spread="1.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" spread="1.837"/>
                    <measurement group_id="O2" value="11.32" spread="1.751"/>
                    <measurement group_id="O3" value="11.50" spread="1.261"/>
                    <measurement group_id="O4" value="10.90" spread="1.340"/>
                    <measurement group_id="O5" value="0.58" spread="1.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.11" spread="1.845"/>
                    <measurement group_id="O2" value="9.04" spread="1.794"/>
                    <measurement group_id="O3" value="8.93" spread="1.272"/>
                    <measurement group_id="O4" value="11.94" spread="1.359"/>
                    <measurement group_id="O5" value="1.29" spread="1.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="1.952"/>
                    <measurement group_id="O2" value="7.75" spread="1.839"/>
                    <measurement group_id="O3" value="8.05" spread="1.347"/>
                    <measurement group_id="O4" value="7.59" spread="1.432"/>
                    <measurement group_id="O5" value="0.18" spread="1.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-minute MWT From Baseline to Week 4</title>
        <description>Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to week 4.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>37.5 mg of JZP-110</title>
            <description>37.5 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>75 mg of JZP-110</title>
            <description>75 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>150 mg of JZP-110</title>
            <description>Subjects randomized to receive 150 mg JZP-110 initially received 75 mg JZP-110 from Day 1 through Day 3 of the treatment phase, and received 150 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O4">
            <title>300 mg of JZP-110</title>
            <description>Subjects randomized to receive 300 mg JZP-110 initially received 150 mg JZP-110 from Day 1 through Day 3 of the treatment phase and received 300 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally, QD, for the 12 week treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-minute MWT From Baseline to Week 4</title>
          <description>Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to week 4.</description>
          <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.53" spread="1.360"/>
                    <measurement group_id="O2" value="7.20" spread="1.307"/>
                    <measurement group_id="O3" value="11.69" spread="0.932"/>
                    <measurement group_id="O4" value="13.77" spread="0.976"/>
                    <measurement group_id="O5" value="1.24" spread="0.942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ESS Score From Baseline to Week 1, Week 4, and Week 8</title>
        <description>Change in Epworth Sleepiness Scale (ESS) score from Baseline to Weeks 1, 4, and 8. A negative change from baseline represents improvement in excessive sleepiness.
The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.</description>
        <time_frame>Baseline to Weeks 1, 4, and 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>37.5 mg of JZP-110</title>
            <description>37.5 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>75 mg of JZP-110</title>
            <description>75 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>150 mg of JZP-110</title>
            <description>Subjects randomized to receive 150 mg JZP-110 initially received 75 mg JZP-110 from Day 1 through Day 3 of the treatment phase, and received 150 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O4">
            <title>300 mg of JZP-110</title>
            <description>Subjects randomized to receive 300 mg JZP-110 initially received 150 mg JZP-110 from Day 1 through Day 3 of the treatment phase and received 300 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally, QD, for the 12 week treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ESS Score From Baseline to Week 1, Week 4, and Week 8</title>
          <description>Change in Epworth Sleepiness Scale (ESS) score from Baseline to Weeks 1, 4, and 8. A negative change from baseline represents improvement in excessive sleepiness.
The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.</description>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="0.66"/>
                    <measurement group_id="O2" value="-4.4" spread="0.65"/>
                    <measurement group_id="O3" value="-5.5" spread="0.46"/>
                    <measurement group_id="O4" value="-6.6" spread="0.46"/>
                    <measurement group_id="O5" value="-2.6" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="0.65"/>
                    <measurement group_id="O2" value="-4.8" spread="0.63"/>
                    <measurement group_id="O3" value="-6.1" spread="0.45"/>
                    <measurement group_id="O4" value="-6.6" spread="0.46"/>
                    <measurement group_id="O5" value="-2.9" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="0.70"/>
                    <measurement group_id="O2" value="-6.3" spread="0.67"/>
                    <measurement group_id="O3" value="-6.9" spread="0.48"/>
                    <measurement group_id="O4" value="-7.7" spread="0.50"/>
                    <measurement group_id="O5" value="-3.8" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Reported as Improved on the PGIc at Week 1, Week 4, and Week 8</title>
        <description>Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 1, Week 4, and Week 8. PGIc was rated by subjects and measures the change in their condition since treatment start on a 7-point scale ranging from 1 = very much improved to 7 = very much worse.</description>
        <time_frame>Weeks 1, 4, and 8</time_frame>
        <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>37.5 mg of JZP-110</title>
            <description>37.5 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>75 mg of JZP-110</title>
            <description>75 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>150 mg of JZP-110</title>
            <description>Subjects randomized to receive 150 mg JZP-110 initially received 75 mg JZP-110 from Day 1 through Day 3 of the treatment phase, and received 150 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O4">
            <title>300 mg of JZP-110</title>
            <description>Subjects randomized to receive 300 mg JZP-110 initially received 150 mg JZP-110 from Day 1 through Day 3 of the treatment phase and received 300 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally, QD, for the 12 week treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reported as Improved on the PGIc at Week 1, Week 4, and Week 8</title>
          <description>Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 1, Week 4, and Week 8. PGIc was rated by subjects and measures the change in their condition since treatment start on a 7-point scale ranging from 1 = very much improved to 7 = very much worse.</description>
          <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9"/>
                    <measurement group_id="O2" value="65.5"/>
                    <measurement group_id="O3" value="78.3"/>
                    <measurement group_id="O4" value="82.5"/>
                    <measurement group_id="O5" value="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                    <measurement group_id="O2" value="77.6"/>
                    <measurement group_id="O3" value="84.5"/>
                    <measurement group_id="O4" value="84.3"/>
                    <measurement group_id="O5" value="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="79.3"/>
                    <measurement group_id="O3" value="88.8"/>
                    <measurement group_id="O4" value="87.8"/>
                    <measurement group_id="O5" value="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Reported as Improved on the Clinical Global Impression of Change (CGIc) at Week 12</title>
        <description>Percentage of subjects reported as improved (minimally, much, or very much) on the CGIc at Week 12. CGIc was rated by clinicians and measures the change in the subject's condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.</description>
        <time_frame>Week 12</time_frame>
        <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>37.5 mg of JZP-110</title>
            <description>37.5 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>75 mg of JZP-110</title>
            <description>75 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>150 mg of JZP-110</title>
            <description>Subjects randomized to receive 150 mg JZP-110 initially received 75 mg JZP-110 from Day 1 through Day 3 of the treatment phase, and received 150 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O4">
            <title>300 mg of JZP-110</title>
            <description>Subjects randomized to receive 300 mg JZP-110 initially received 150 mg JZP-110 from Day 1 through Day 3 of the treatment phase and received 300 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally, QD, for the 12 week treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reported as Improved on the Clinical Global Impression of Change (CGIc) at Week 12</title>
          <description>Percentage of subjects reported as improved (minimally, much, or very much) on the CGIc at Week 12. CGIc was rated by clinicians and measures the change in the subject's condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.</description>
          <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9"/>
                    <measurement group_id="O2" value="70.7"/>
                    <measurement group_id="O3" value="90.5"/>
                    <measurement group_id="O4" value="88.7"/>
                    <measurement group_id="O5" value="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Reported as Improved on the CGIc at Week 1, Week 4, and Week 8</title>
        <description>Percentage of subjects reported as improved (minimally, much, or very much) on the CGIc at Week 1, Week 4, and Week 8. CGIc was rated by clinicians and measures the change in the subject's condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.</description>
        <time_frame>Weeks 1, 4, and 8</time_frame>
        <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>37.5 mg of JZP-110</title>
            <description>37.5 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>75 mg of JZP-110</title>
            <description>75 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>150 mg of JZP-110</title>
            <description>Subjects randomized to receive 150 mg JZP-110 initially received 75 mg JZP-110 from Day 1 through Day 3 of the treatment phase, and received 150 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O4">
            <title>300 mg of JZP-110</title>
            <description>Subjects randomized to receive 300 mg JZP-110 initially received 150 mg JZP-110 from Day 1 through Day 3 of the treatment phase and received 300 mg JZP-110 starting on Day 4, administered orally, QD.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally, QD, for the 12 week treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reported as Improved on the CGIc at Week 1, Week 4, and Week 8</title>
          <description>Percentage of subjects reported as improved (minimally, much, or very much) on the CGIc at Week 1, Week 4, and Week 8. CGIc was rated by clinicians and measures the change in the subject's condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.</description>
          <population>Fifteen subjects in the Safety Population were excluded from the mITT Population resulting in a total of 459 subjects.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="60.3"/>
                    <measurement group_id="O3" value="75.7"/>
                    <measurement group_id="O4" value="82.6"/>
                    <measurement group_id="O5" value="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                    <measurement group_id="O2" value="77.6"/>
                    <measurement group_id="O3" value="85.2"/>
                    <measurement group_id="O4" value="81.7"/>
                    <measurement group_id="O5" value="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4"/>
                    <measurement group_id="O2" value="74.1"/>
                    <measurement group_id="O3" value="87.8"/>
                    <measurement group_id="O4" value="87.8"/>
                    <measurement group_id="O5" value="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through Week 14</time_frame>
      <group_list>
        <group group_id="E1">
          <title>37.5 mg of JZP-110</title>
          <description>37.5 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
        </group>
        <group group_id="E2">
          <title>75 mg of JZP-110</title>
          <description>75 mg JZP-110 administered orally, QD, for the 12-week treatment phase.</description>
        </group>
        <group group_id="E3">
          <title>150 mg of JZP-110</title>
          <description>Subjects randomized to receive 150 mg JZP-110 initially received 75 mg JZP-110 from Day 1 through Day 3 of the treatment phase, and received 150 mg JZP-110 starting on Day 4, administered orally, QD.</description>
        </group>
        <group group_id="E4">
          <title>300 mg of JZP-110</title>
          <description>Subjects randomized to receive 300 mg JZP-110 initially received 150 mg JZP-110 from Day 1 through Day 3 of the treatment phase and received 300 mg JZP-110 starting on Day 4, administered orally, QD.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo administered orally, QD, for the 12 week treatment phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Streptococcal endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Disclosure &amp; Transparency</name_or_title>
      <organization>Jazz Pharmaceuticals</organization>
      <phone>2158709177</phone>
      <email>ClinicalTrialDisclosure@JazzPharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

